| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
|
US8420596 (Pediatric) | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(7 years from now) | |
Technivie is owned by Abbvie.
Technivie contains Ombitasvir; Paritaprevir; Ritonavir.
Technivie has a total of 19 drug patents out of which 8 drug patents have expired.
Expired drug patents of Technivie are:
- US6703403
- US6037157
- US6037157*PED
- US6703403*PED
- US7148359
- US7148359*PED
- US7364752
- US7364752*PED
Technivie was authorised for market use on 24 July, 2015.
Technivie is available in tablet;oral dosage forms.
Technivie can be used as use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection, treatment of hcv infection using ombitasvir, treatment of hcv infection using paritaprevir.
Drug patent challenges can be filed against Technivie from 19 December, 2018.
The generics of Technivie are possible to be released after 13 April, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2018 |
| New Indication(I-743) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using ombitasvir...
Dosage: TABLET;ORAL
TECHNIVIE family patents
